Shanghai MicroPort EP MedTech's (SHA:688351) forecasts its attributable profit will rise 76% to 106% to between 30 million yuan and 35 million yuan in the first half from 17 million yuan in the prior-year period, according to a Wednesday filing with the Shanghai bourse.
Operating income at the medical device company is seen to grow 8.4% to 16% to between 215 million yuan and 230 million yuan during the half, from 198.4 million yuan in the year-ago period.
The upbeat forecast is attributable to steady growth in its overall sales volume following the launch of its TrueForce pressure monitoring radiofrequency ablation catheters, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.